Jason MacGurn and colleagues have characterized a “rheostat” that sets WNT pathway signaling in breast cancer cells.

Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman’s risk for developing lymphedema, painful swelling in the arm after breast cancer surgery, according to interim results of a recent study.

Finding gives boost to fighting cancer through cell metabolism

A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.

Charles Caskey, Ph.D., has received a cancer research grant from The Mary Kay Foundation to study how focused ultrasound therapy could be an ideal helper for immunotherapy.

Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program, has been named a Komen Scholar for her leadership in breast cancer research. She is joined by Wayne Dornan, PhD, a patient research advocate at VICC, who will serve on the Advocates in Science Steering Committee for Susan G. Komen.

Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.